Sarepta Therapeutics’ Duchenne therapy faces ‘arduous’ path back to market, senior FDA official says

What impact did Trump’s Japan trade deal have on auto stocks? How are tariffs affecting General Motors’ profits? Why is Coca-Cola launching a cane sugar soda? What caused the Nikkei to surge recently? How are US-Japan tariffs influencing Asian markets? Why did Amazon shut its Shanghai AI research lab? What’s driving the rise in US electricity costs?

Sarepta Therapeutics’ Duchenne therapy faces ‘arduous’ path back to market, senior FDA official says

statnews.com/2025/07/22/fda-sarepta-elevidys-muscular-dystrophy-drug

Sarepta Therapeutics, the maker of a gene therapy for Duchenne muscular dystrophy that is being temporarily shelved because of safety concerns, faces an “arduous and treacherous path” to try to get it back onto the market, a senior Food and Drug Administration official told STAT,…

This story appeared on statnews.com, 2025-07-22 19:47:05.130000.